Related by context. All words. (Click for frequent words.) 62 Proposing Release 60 END FOOTNOTE 60 Exposure Draft 60 ANPRM 59 National Coverage Determination 59 Proposed Rule 58 Tailoring Rule 58 proposed rulemaking NPRM 58 DMEPOS supplier 58 HIPAA Privacy Rule 57 NPRM 57 Rev. Rul 56 Revised Guidelines 56 FDAAA 56 Complete Response 56 Interpretative Communication 56 Registry NOPR 55 FNPRM 55 EFFECTIVE DATE 55 MHPAEA 55 BCIRG 55 Physician Fee 55 MMSEA 55 NSQIP 55 Proposed Regulations 55 Amending Directive 55 National Oncologic PET 55 CAISO 55 Notice #-# [002] 54 Reliability Standards 54 APEX AMI trial 54 Exposure Drafts 54 SLHCs 54 LTCH PPS 54 FSCO 54 FDG PET 54 Subpart E 54 TSCorp 54 Schedule UTP 54 NUREG 54 Triennial Review 54 Accelerated Approval 54 Appendix VII 54 MPFS 54 Centralized Procedure 54 PIX# [002] 54 Computed Tomographic 54 EGTT 54 PRRB 53 IUR 53 Tumor Response 53 Confirmatory Order 53 NGER 53 § #.# [002] 53 EITE assistance 53 Notice #-# [001] 53 #F FDG PET 53 CFR § #.# [007] 53 MGCD# clinical trials 53 CP#/# 53 adjuvant systemic 53 predecisional 53 APEX AMI 53 NGERS 53 HCAHPS survey 53 SUPPLEMENTARY INFORMATION 53 RUG IV 53 F FDG PET 53 Subsection b 53 USDE 53 CAQH CORE 53 EPCRS 53 CFR #.# c 53 rulemaking proceeding 52 BEIR 52 CFR § #.# [001] 52 Scoping Plan 52 PUCT 52 STRIDE PD 52 CDM EB 52 MIPPA 52 PJM Interconnection PJM 52 FREP 52 programmatic EIS 52 GPNMB expression 52 LSA RS #:# [001] 52 CFR § #.# [006] 52 Hospital Outpatient Prospective 52 AIDAC 52 MRTU 52 CWMP 52 ERRP 52 Recommended Practices 52 § #:# [001] 52 SACGHS 52 Proposed Rulemaking NOPR 52 Coronary Revascularization 52 AHQA 52 Subtitle D 52 ONCHIT 52 Appropriateness Criteria 52 NYPSC 52 RREs 52 Proposed Arrangement 52 ACS NSQIP 52 ratemaking principles 52 Enabling Clause 52 CFR § #.# [005] 52 rulemaking 52 CFR #.# [008] 52 Lamfalussy process 52 RECIST Response Evaluation Criteria 52 HFMA Peer Reviewed 52 § #B#.# [002] 52 MAQC 52 Ark. Sup 51 ACCME 51 HCPCS codes 51 Rev. Proc 51 DICOM RT 51 Investigational Drugs 51 NCUC 51 Expedited Review 51 multivariate regression analysis 51 CFR #.# d 51 Counterparty Criteria 51 IASB FASB 51 Cardiopulmonary bypass 51 NCPDP SCRIPT 51 MPUC 51 Penalty Guidelines 51 eCTD format 51 SWHCS 51 ACCF AHA 51 MS DRGs 51 Proposed Rulemaking NPRM 51 myocardial revascularization 51 Interagency Registry 51 IRP# 51 HealthMetrix Research 51 PLCO 51 CICA Accounting Guideline 51 BrachySil TM 51 OPPS 51 DFARS 51 OATT 51 Proposed Rule Making 51 EMPHASIS HF 51 TLR antagonist 51 Vapor Intrusion 51 RFS2 51 Orderly Liquidation Authority 51 Determination Letter 51 QOPI 51 FANR 51 MedPAC recommendations 51 Interagency Coordinating Committee 51 FDG PET imaging 51 MGd 51 ACR accreditation 51 STELA 51 Notified Bodies 51 multicenter trials 51 Accounting Guideline 51 MVax 51 CYP #D# 51 Shared Savings 51 DOE NNSA 51 CALGB 51 DMEPOS suppliers 51 EIS OEIS 51 Workplan 51 Pa.RAP 51 NCCN Drugs & 51 NGER Act 51 Code § #A [002] 51 subparagraph b 51 CFR pt 51 NDCC ch 51 Physician Quality 51 FINRA Rule 51 FIPPA 51 Guidance Document 51 FDA Accelerated Approval 51 TRECs 51 RIGScan CR 51 RTOG 51 RadPort 51 Acute Decompensated Heart Failure 51 Patient Protections 51 LSA RS #:# [002] 51 NSABP 51 contemporaneous documentation 51 Section #I 51 DXA scan 51 REACH Registry 51 Programmatic Environmental Impact Statement 51 Revenue Procedure 51 Provider Reimbursement 50 MedPac 50 ERISA § 50 FDG PET scan 50 OCGA § #-#-# [007] 50 biologic DMARDs 50 Antisoma AS# 50 Interpretive Guidance 50 Ark. R. Civ 50 SR NYSEArca 50 preoperative MRI 50 Fuel Adjustment Clause 50 WDEQ 50 proposed rulemaking 50 Percutaneous Coronary Interventions 50 § #.#.# [001] 50 Human Epigenome Project 50 Tenn. R. Civ 50 Consultation Document 50 FERC 50 § #.#.# [002] 50 La. Code Civ 50 EPACT 50 PUCN 50 Subgroup analyzes 50 Subtitle B 50 Pricing Supplement 50 JACR 50 ACHP 50 Randomized Controlled Trials 50 IPUC 50 Tariff Policy 50 Neuradiab 50 chemoprevention trials 50 LDTs 50 Regulatory Impact Statement 50 histopathologic 50 HSCRC 50 HORIZONS AMI trial 50 Rate Adjustment 50 NCCUSL 50 CTEPH 50 Zevalin consolidation 50 MAGE A3 ASCI 50 FAR clauses 50 Submittals 50 SASSA tender 50 NCCN Guidelines ™ 50 La.Civ.Code art 50 ARS § 50 NCCN Drugs 50 Subtitle C 50 NCDB 50 MYTO 50 Resolute DES 50 Marketing Authorizations 50 Draft Scoping 50 RUGs IV 50 sipuleucel T 50 QACA 50 NPSs 50 explanatory memoranda 50 NJSA #:#-# [004] 50 NCCN guidelines 50 SVEP 50 Consultation Paper 50 ICERA 50 Simplified Prospectus 50 Sources Sought 50 EMTALA 50 SR ISE 50 CFR § #.# [004] 50 MERLIN TIMI 50 CPUC 50 oral alitretinoin 50 Phynance 50 FASB Interpretation 50 Dacogen injection 49 ClinicalTrials.gov 49 Practice Guideline 49 TxLED 49 Erythropoiesis Stimulating Agents ESAs 49 IPPS 49 APTIVUS ritonavir 49 interconnected VoIP 49 MS DRG 49 Subsidiary Arrangements 49 MACT standards 49 SDEIS 49 OCABR 49 PITX2 methylation 49 NRSRO ratings 49 CEHE 49 recurrent GBM 49 Stretta procedure 49 multimodality therapy 49 interferon γ 49 ARIXTRA R 49 ACRIN 49 CSR #-#.# 49 SABCS 49 Biological Effects 49 YESAB 49 FDA Modernization Act 49 ETAAC 49 Section #.# [001] 49 Implementation Guides 49 Greenhouse Gas GHG 49 lymph node dissection 49 TWGs 49 QuadraSphere 49 PMPRB 49 FSOC 49 MISRA C + 49 MTWA testing 49 PM#.# NAAQS 49 Grandfathered Plans 49 CAHs 49 Act PURPA 49 CFR #.# [002] 49 OMIG 49 adopting IFRS 49 neoadjuvant treatment 49 PCWP 49 substudy 49 SGIP 49 USPSTF 49 NCCN Clinical Practice Guidelines 49 GRI Guidelines 49 Proposed Rulemaking 49 Biomarkers Consortium 49 ORS #B.# 49 Horizontal Merger Guidelines 49 NASD Rule 49 #/#/EC [001] 49 HITSP 49 prospectively 49 LGIC 49 CPT code 49 Add.1 49 CREZ 49 Covered Entity 49 factorial design 49 Ferc 49 Unfunded Mandates Reform Act 49 postapproval 49 logistic regression models 49 EFAST2 49 Dietary Reference Intakes 49 ERGEG 49 lymphadenectomy 49 ratemaking 49 MAA submission 49 OIG 49 Proposed Revisions 49 atherothrombotic disease 49 FCC Triennial Review 49 INTERMACS 49 JNNSM 49 ANATEL 49 SCRs 49 CAH designation 49 OHRP 49 SIEF 49 Final EIS 49 requestor petitioner 49 § #-#-# [002] 49 non selective NSAIDs 49 ARRA HITECH 49 NICE SUGAR 49 Submittal 49 ENRICH trial 49 allogeneic SCT 49 PURPA 49 Intercreditor 49 NRSROs 49 tele ICU 49 NGNP 49 Radiation Therapy Oncology 49 PCII 49 Solicitation Number 49 EPER 49 USC § #f 49 Teleradiology Partners 49 PHC4 49 substitute SBPA 49 Disclosure Document 49 Pensions Regulator TPR 49 GHG Tailoring Rule 49 Regulatory Flexibility Act 49 Premerger Notification 49 CICA Emerging 49 postmarketing surveillance 49 NIH grantees 49 EFSA GMO Panel 49 Medicare Secondary Payer 49 CICA Section 49 Patient Centered Outcomes 49 WAC #-#-# 49 PROPEL trial 49 Clinical Practice Guideline 49 HACs 49 Draft EIS 49 DRGs 49 section #A.# [001] 49 FEDVIP 49 Ranolazine 49 Dr. Gulfo 49 Variable Interest Entities FIN 49 Exelixis XL# 49 Greenhouse Gas Reporting 49 La.Code Crim.P. art 49 USSG § #B#.# [002] 49 Freeny patent 49 Toxics Rule 49 RCEs 49 Improving Outcomes 49 NCOIL model 49 IRPAC 49 NPRM proposes 49 Medicare Reimbursement 49 FDG-PET/CT 49 Vectibix monotherapy 49 oral anticoagulation 49 CT Colonography 49 jurisdictional thresholds 49 SFAS No.# 49 TNM staging 49 pelvic lymphadenectomy 49 Angiox ® 48 intraobserver 48 Prognostic Value 48 PSCW 48 Determinations Panel 48 AIM HIGH 48 orphan designation 48 KRS #A.# [002] 48 PLR # 48 eTag assays 48 CMPs 48 ascertainment 48 ACC AHA 48 CFR § #.# [002] 48 Panel SGIP 48 Dacogen TM 48 COP MOP 48 NHSN 48 Position Statement 48 GISCI 48 ANSI C#.# 48 Quality Indicators 48 EBMT criteria 48 neoadjuvant therapy 48 surrogate endpoint 48 s#A [001] 48 Solvency II Directive 48 Commissioner Dian Grueneich 48 CFR #.# [007] 48 CPT coding 48 Solid Tumors 48 subparts 48 Cesr 48 PRECISE trial 48 RACs 48 oBIX 48 National Provider Identifier 48 BEIR VII 48 NJBPU 48 BCR ABL1 48 FGDC 48 MDUFMA 48 FFIs 48 EOBR mandate 48 Dr. Yatscoff 48 NQF endorsed 48 OVDI 48 MB Docket 48 DNA methylation markers 48 MBTOC 48 DOT OST 48 Cinacalcet HCl 48 subgroup analyzes 48 codes #-# 48 CEII 48 PRESEPT 48 ICD Registry 48 La.Code Civ.P. art 48 Premarket Approval 48 Discussion Paper 48 BARI 2D 48 SLN biopsy 48 etiologic 48 Covered Entities 48 MSRB Rule G 48 AGRSS Standard 48 GERC 48 CPT codes 48 ORWH 48 secondary efficacy endpoint 48 chemoradiation therapy 48 IASLC 48 ASC #-#-# 48 www.ferc.gov 48 QTDP Program 48 FFDCA 48 Mortgagee Letter 48 MEDMARX 48 sDNA 48 Work SOW 48 Rule #h 48 ICOB 48 IDTF 48 Acid Rain Program 48 IFRS changeover 48 ISTODAX 48 interinstitutional 48 Rulemaking 48 Meaningful Use Workgroup 48 ICAEL 48 GPRD 48 FASB ASC #-# 48 LTCHs 48 GPRA 48 SYMMETRY trial 48 FAR #.# 48 Locational Installed Capacity 48 NJSA #:#-#.# [003] 48 NCCN Compendium 48 PTNS 48 MVEIRB 48 Rule #:#-# b 48 laparoscopic radical nephrectomy 48 static synthetic CDO 48 Confirmatory 48 Remand Order 48 nullhe 48 ORS #.# [001] 48 Ann Oncol 48 microplasmin Phase III 48 Medicaid RACs 48 ECFS 48 Authority OPA 48 Stipulated Order 48 inspectional observations 48 AVADO 48 Summary Prospectus 48 Prostate Cancer Outcomes 48 Carotid Revascularization Endarterectomy vs. 48 UVIDEM 48 Dr. Zelenetz 48 ICMJE 48 Carotid Artery Stenting 48 National Guideline Clearinghouse 48 Triage Stroke Panel 48 Subsection c 48 La. RS #:# [003] 48 EOquin TM 48 Option IVC Filter 48 Octreolin 48 ACC NCDR 48 Aquaculture Stewardship Council 48 FSP FAS #-# 48 Colorado Revised Statutes 48 Pharmacokinetic parameters 48 Mammographic 48 potentiostat 48 randomizing patients 48 Liver Fibrosis 48 MEND CABG II 48 RE LY 48 Ohio Adm.Code #-#-# 48 Transmission Expansion 48 Hepatotoxicity 48 bone scintigraphy 48 PIX# trial 48 Arbortext IsoDraw 48 chest radiographs 48 differential gene expression 48 Trial PCPT 48 Quotation RFQ 48 retrospective observational study 48 MVLWB 48 Financial Reporting Interpretations 48 Interrogatory No. 48 GnRH agonists 48 RRGs 48 Specified Investment 48 transcriptional profiling 48 GASB Issues 48 LSTA 48 FOIA exemption 48 FATCA 48 PKC isozymes 48 ABLAVAR ™ 48 OvaRex MAb 48 Cryoablation 48 Percutaneous Coronary Intervention 48 Risk Equalisation Fund 48 SCENIHR 48 PDSs 48 prospective multicenter study 48 MQSA 48 Velcade bortezomib 48 RE LY trial 48 neoadjuvant 48 Control DPUC 48 gene rearrangements 48 COR Analyzer 48 APPRAISE 48 telavancin NDA 48 BEXXAR therapeutic regimen 48 CBRS 48 § #.# [004] 48 Periodic Review 47 Corrective Action Order 47 CPMP 47 multivariate analyzes 47 ASC X# 47 NPSTC 47 ICSID Convention 47 GeneCards R 47 NSP2 47 Boiler MACT 47 Eligibility Requirements 47 OraTest R 47 Sunesis Pharma 47 PhRMA Code 47 chromosome #p# [002] 47 CMS 47 decoupling mechanism 47 IRTPA 47 QHSR 47 OSEP 47 BSIs 47 BLA filing 47 RC #.# F 47 clinicopathological 47 fludarabine cyclophosphamide 47 GSK# [001] 47 clinicopathologic 47 scintigraphic 47 E2B 47 colorectal liver metastases 47 QTDP grant 47 ISSN #-# 47 eValue8 47 AMA CPT 47 Natalizumab 47 § #A [003] 47 LSA CCP art 47 DATES Written comments 47 eosinophilic pneumonia 47 sNDA submission 47 FoxP3 47 NPDB 47 IETF RFC 47 WHO prequalification 47 Standardized Approach 47 PSRI 47 EPBD 47 subpart 47 ICCD COP 7 47 Digital Mammographic Imaging 47 FDA Advisory Panel 47 MR Civ 47 NIST Smart Grid 47 microsimulation model 47 GFT# 47 PRECISE Trial 47 BPH LUTS 47 Medicare Physician Fee 47 EDSP 47 Total OnBoarding ™ 47 Act PDUFA 47 CIRs 47 Categorical Exclusion 47 ICD implantations 47 NIETC 47 EuroSCORE 47 OEB 47 DC Code § 47 aldosterone antagonist therapy 47 NCQA accreditation 47 retrospective cohort study 47 DSM IV diagnoses 47 Acquisition Regulation FAR 47 AVERROES 47 adjudicatory proceedings 47 XSPA 47 Stormwater Permit 47 cGMPs 47 EITF Topic D 47 GENASIS trial 47 Colorectal Screening 47 Carotid endarterectomy 47 Remuneration Code 47 clopidogrel pretreatment 47 Continuous Disclosure Policy 47 ADAAG 47 IL#B 47 GRAVITAS trial 47 ALLHAT 47 Sanofi Acomplia 47 Scheduling Order 47 ESML Intressenter AB 47 Combined License Application 47 Rule #:#-# [002] 47 EIR EIS 47 Options Symbology Initiative 47 CFR § #.# [008] 47 Mantel Haenszel 47 chest radiography 47 EU Directive #/#/EC 47 NACI 47 ISO IEC JTC 47 CFR #.# [006] 47 TNERC 47 #F FDG PET CT 47 HIF 1a 47 § #-#.# [002] 47 ECLS 47 PROactive study 47 Competitive Impact Statement 47 pharmacoeconomic analysis 47 IFRD1 47 Scientific Advice 47 HSCT 47 ProviderPoint 47 Intervention Trial GAIT 47 SBLF 47 Recent Accounting Pronouncements 47 Electronic Brachytherapy 47 Appendix 4E 47 GHG Inventory 47 CEQA Guidelines 47 MedPAC 47 residual confounding 47 Prospective Multicenter 47 KIID 47 DFAR 47 WUTC 47 FR # [001] 47 Concession Arrangements 47 ESSB 47 LRET 47 Draft SEIS 47 Renewables Obligation RO 47 ECAF 47 eEurope 47 Plan RTEP 47 Oligonucleotide Therapeutics Society 47 estimated GFR 47 CAMMS# 47 CRp 47 antiangiogenic therapy 47 CHMP recommendation 47 Program TLGP 47 FDA Adverse Event 47 ERSPC 47 COPPA Rule 47 rFVIIa 47 SEDAR www.sedar.com www.sedar.com 47 chemotherapeutic regimen 47 nephrogenic fibrosing dermopathy 47 USC § #b [002] 47 Clinical Trial Data 47 FMIA 47 NPIs 47 Outpatient Prospective Payment 47 Shelf Registration 47 CEAA 47 Syllego system 47 RC #.# B [001] 47 SYNTAX trial 47 Schedule #N 47 pharmacogenetic testing 47 c myb 47 FSMB 47 GPSD 47 Applicant Guidebook 47 MIST II 47 chromium supplementation 47 CFATS 47 perfusion imaging 47 NRMP 47 CPT Codes 47 Daxor 47 Public Contracts Regulations 47 OSC Policy 47 Trofex 47 reperfusion therapy 47 Glybera R 47 Adjustment Clause 47 IRFs 47 Fampridine SR NDA 47 Thrombolysis 47 Multimodality 47 Clinger Cohen 47 Transparency Directive 47 Guides Concerning 47 Grandfathered Plan 47 ERDs 47 curative resection 47 Subtopic #-# 47 Plenaxis R 47 ICD implantation 47 RPSs 47 CRD3 47 Antigen CEA 47 ISOO 47 NCCLS 47 CRNs 47 ozone NAAQS 47 CCDF 47 TIMP 1 47 SEIR 47 Pediatric Oncology Branch 47 Tax Clearance Certificate 47 § #.# Vernon 47 metastatic RCC 47 CPCN 47 Screening Trial DMIST 47 elective PCI 47 System HCPCS 47 Regulatory Impact Assessment 47 Clinical Guideline 47 NSIP 47 reh'g 47 NTIOL 47 ENDEAVOR clinical 47 CFR #.# b 47 MEPAG 47 SRDP 47 FSAP 47 Meta analyzes 47 Lp PLA 2 47 Euratom treaty 47 CHAMPION PCI 47 MDRD equation 47 EIA Notification 47 USC § #u 47 Autorité 47 Comparative Effectiveness 47 DAAs 47 nipple aspirate fluid 47 codecision procedure 47 HNRC 47 PAPUC 47 adjuvant radiotherapy 47 Orathecin 47 Orphan Drugs 47 draft Supplemental Generic 47 Fed.R.Civ.P. 47 Interconnection Regulation 47 LSGP 47 comitology 47 Accountable Care Organizations ACOs 47 FSP EITF #-#-# [002] 47 Revenue Memorandum Circular 47 Phase IIB 47 Autograft 47 Fact Conclusions 47 selenium supplementation 47 NICE guideline 47 SCD HeFT 47 Aortic Dissection 47 clinico pathological 47 AEPS 47 empirically validated 47 Smallpox Vaccination Program 47 TEAP 47 Corrective Action Plan 47 Uterine Cancer 47 LUMINATE 47 SLNB 47 relapsed MCL 47 Rule 2a 7 47 LBDP 47 UARB 47 Filing Requirements 47 prospective observational studies 47 nodal dissection 47 nonrandomized studies 47 UCITS Directive 47 Final Appraisal Determination 47 Gynecol Oncol 47 EPA HQ OAR 47 KRAS status 47 Biologics Compendium 47 CICA Handbook section 47 HIPAA HITECH 47 Decision #/#/EC 47 nodal metastases 47 NJRE 47 nomograms 47 CAQ 47 SBSTA 47 Outpatient Setting 47 PERM Rule 47 Plaintiffs Complaint 47 MADIT II 47 CORE Phase 47 LRRA 47 DATES Comments 47 Original Bidder Statement 47 Anticalin ® 47 PQRI 47 Directive #/#/EU 47 ERBs 47 HSDA 46 Devices Advisory Panel 46 Loss Severity 46 ChromoCure 46 EchoCRT 46 prognostic variables 46 Genomic Grade 46 ReN# 46 FDG PET scans 46 § #.# [005] 46 #m Tc 46 GridPoint Platform 46 FDA Approvable Letter 46 C.3 46 predefined criteria 46 SWOG 46 Reporting Initiative PQRI 46 Second Supplemental Indenture 46 INIF 46 Disease GOLD 46 multivariable analysis 46 GL c 46 Crit Line 46 EDPS 46 iApprove 46 SAAs 46 Slip op 46 Reports CTRs 46 Ann Emerg Med 46 guideline concordant 46 Predictive Toxicology 46 CIBMTR 46 Pharmacopoeia USP 46 Dialysis Outcomes 46 NAPs 46 Am J Epidemiol 46 Review Panel JRP 46 mITT 46 Swap Execution 46 Newborn Screening Saves Lives 46 Pre IND 46 QDIA 46 URAC Accreditation 46 #.#-# Offeror Representations 46 Journal Editors ICMJE 46 Qualified Therapeutic Discovery 46 nonfinal 46 EFRAG 46 Paperwork Reduction Act 46 TheraSphere R 46 inter partes reexamination 46 actuarially equivalent 46 HCV SPRINT 46 FASB ASC 46 ISTH 46 nonprecedential 46 ECD kidneys 46 SERFF 46 IECs 46 lorcaserin NDA 46 ABCP conduits 46 § #-#.# [004] 46 Phase III TRIST 46 carotid artery stenting 46 TAGP 46 Stub Period 46 Improvement Amendments 46 dose escalation phase 46 DOE NETL 46 Wyo. Stat 46 precertification 46 Chronic Lyme Disease 46 SF #v# 46 purposive approach 46 multicenter clinical trials 46 TWYNSTA 46 Postmarket 46 Voluntary Consensus 46 IMPROVE HF 46 Consensus Statement 46 ENDEAVOR IV 46 empiric 46 postoperative chemotherapy 46 medically inoperable 46 Initiative K DOQI 46 PDEIS 46 NSPIRES 46 USDOC 46 epoetin therapy 46 actuarially justified 46 Rating Outlooks 46 NRSRO designation